Partnering with GSK

Partnerships that matter

We innovate with others, because no single scientist, nor any one technology, can keep us ahead of disease. We forge partnerships to drive innovation and tackle challenging diseases. By fostering a network of trust with our partners, we're able to deliver new treatment options and innovative medicines to patients, better and faster.

2:46

Partnerships

We have been working with Wave Life Sciences on RNA editing with the aim of transforming lives

How we engage

We believe in the power of collaboration as a component of our wider R&D strategy to drive innovation. We engage and collaborate with outstanding scientists at academic institutions and across biopharma, working together to accelerate the discovery and development of new medicines and vaccines. By combining expertise and resources, we can unlock new insights and bring life-saving treatments to patients more efficiently.

Partner with us

Submit ideas or contact us for collaboration opportunities:

Some of our recent collaborations

By working with partners, we can achieve more and ensure faster innovation to address disease areas of high unmet need for as many people as possible. Our collaborations with our partners underscore our commitment to finding novel treatments to improve the quality of life of patients suffering from underserved diseases.

Oxford

The University of Oxford, a world renowned research institution, and GSK have launched an immuno-prevention programme to advance novel cancer research. This research could then be used to inform future development of vaccines to prevent cancer.

The collaboration will enhance the already established research agreement between Oxford and GSK, which includes the existing five-year collaboration to establish the Oxford-GSK Institute of Molecular and Computational Medicine.

Scientists talking and laughing in a lab

Muna

Muna Therapeutics is a biotechnology company focused on developing innovative therapeutics for neurodegenerative diseases.

The GSK and Muna research collaboration will leverage Muna’s MiND-MAP platform to identify and validate new therapeutic targets for Alzheimer’s disease, potentially leading to new treatments for patients dealing with significant unmet need.

Relation

Relation is a leader in integrating wet lab experimentation, computation, and machine learning to enhance drug discovery.

GSK's collaboration with Relation and their patient-centric discovery platform presents a unique opportunity to accelerate the development of new medicines. Relation will conduct observational studies to create two distinct sets of functional disease data, which will then be analysed using Relation's Lab-in-the-Loop platform. The collaboration will focus on the identification and validation of new therapeutic targets for fibrotic diseases and osteoarthritis.